*Faculté de pharmacie, Université de Montréal, Montreal, Canada;

†Laboratoire de suivi thérapeutique pharmacologique et pharmacocinétique, Faculté de pharmacie, Université de Montréal, Montreal, Canada;

‡Department of Pharmacy, McGill University Health Centre, Montreal, Canada;

§Adult Cystic Fibrosis Clinic, Montreal Chest Institute, McGill University, Montreal, Canada;

¶Department of Medicine, McGill University, Montreal, Canada;

‖McGill University Health Center Research Institute, Montreal, Canada;

**Faculté de pharmacie, Université Laval, Quebec, Canada

††Centre de recherche, Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval, Quebec, Canada; and

‡‡Département de pharmacie, Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval, Quebec, Canada.

Correspondence: Mehdi El Hassani, MSc, Faculté de pharmacie, Université de Montréal, 2940 chemin de polytechnique, Montréal H3T 1J4, QC, Canada (e-mail: [email protected]).

Supported in part by the Réseau Québécois de Recherche sur les Médicaments and Canada Foundation for Innovation. Amélie Marsot acknowledges the support from the Fonds de Recherche du Québec-Santé (FRQS) Research Scholars—Junior 1 (Young Researcher Establishment) Career Scholarship.

M. El Hassani and A. Marsot conceptualized and designed the study. M. El Hassani contributed to the analysis and interpretation of the data and drafted the initial manuscript. D. J. G. Thirion, K. Koloskoff, E. Matouk, C. Simard, I. Cloutier, S. Pilote, and A. Marsot critically reviewed and revised the manuscript.

The authors declare no conflict of interest.

The data that support the findings of this study are available upon request from the corresponding author.

Ethical standard statement: The study protocol was approved by the University of Montreal (CERC-21-006-D) and the IUCPQ (MP-32-2020-1904) clinical research ethics Committees.